Our Services
Medical Information
Helpful Resources
Published on: 8/18/2026
It looks like the source content didn't come through with your message. Could you paste the text you'd like summarized? Once I have it, I'll return just the rewritten summary in the format you specified.
Infantile hypophosphatasia (HPP) is a rare inherited disorder caused by a deficiency in the enzyme alkaline phosphatase. While the primary impact is on bone mineralization, disturbances in calcium and phosphate balance can stress the kidneys. Understanding how proper hydration and enzyme replacement therapy (ERT) work together helps protect renal function and improve the long-term outlook—especially when considering the Infantile Hypophosphatasia renal failure prognosis.
In HPP, low alkaline phosphatase activity leads to:
These factors can contribute to renal injury over time. Early recognition and intervention are key to maintaining healthy kidney function and improving the Infantile Hypophosphatasia renal failure prognosis.
Proper fluid balance is the foundation of kidney health. In HPP, maintaining good hydration helps dilute urine, lowers the risk of crystal formation, and supports normal filtration.
Key hydration strategies include:
Always consult your healthcare provider for personalized fluid goals. Overhydration is rare but can occur—work with your care team to find the right balance.
Enzyme replacement therapy with asfotase alfa is approved for managing pediatric HPP. By supplementing alkaline phosphatase, it:
Clinical studies and real-world experience have shown that long-term ERT can slow or prevent the progression of kidney calcifications and preserve glomerular filtration rate (GFR).
When used together, hydration and ERT deliver complementary benefits:
Parents and caregivers often see:
Even with optimal hydration and ERT, ongoing surveillance is essential. Recommended steps include:
Early identification of any renal changes lets your care team adjust fluids, ERT dosage, or dietary factors before significant damage occurs.
With timely diagnosis and a proactive management plan, most infants and children with HPP avoid severe renal failure. Factors that improve prognosis include:
While each child’s journey is unique, the combined approach of hydration plus ERT has shifted the outlook from reactive care to prevention. This proactive stance underpins a more favorable long-term renal prognosis in Infantile Hypophosphatasia.
Hydration “habits”:
Medication schedule:
Dietary balance:
Tracking and communication:
Emergency awareness:
If you notice any new or worsening symptoms—especially those that could signal kidney distress—you might consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. It can help you decide whether a medical visit is needed right away.
Always remember: nothing replaces professional medical advice. Discuss any concerns or life-threatening signs with your healthcare provider as soon as possible.
If you or your child experiences anything that could be life threatening or serious, please speak to a doctor right away.
Remember that early intervention and a coordinated care plan give every child the best chance for healthy kidney function and overall well-being.
(References)
* Lajer H, Daugaard G. Cisplatin and hypomagnesemia. Cancer Treat Rev. 1999 Feb;25(1):47-58. doi: 10.1053/ctrv.1999.0097. PMID: 10212589.
* Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol. 2003 Sep;23(5):460-4. doi: 10.1016/s0270-9295(03)00089-5. PMID: 13680535.
* Germain DP. Fabry disease. Orphanet J Rare Dis. 2010 Nov 22;5:30. doi: 10.1186/1750-1172-5-30. Epub 2010 Nov 22. PMID: 21092187; PMCID: PMC3009617.
* Nijssen EC, Rennenberg RJ, Nelemans PJ, Essers BA, Janssen MM, Vermeeren MA, Ommen VV, Wildberger JE. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet. 2017 Apr 1;389(10076):1312-1322. doi: 10.1016/S0140-6736(17)30057-0. Epub 2017 Feb 21. PMID: 28233565.
* Prowle JR. Sepsis-Associated AKI. Clin J Am Soc Nephrol. 2018 Feb 7;13(2):339-342. doi: 10.2215/CJN.07310717. Epub 2017 Oct 25. PMID: 29070523; PMCID: PMC5967431.
* Finfer S, Myburgh J, Bellomo R. Intravenous fluid therapy in critically ill adults. Nat Rev Nephrol. 2018 Sep;14(9):541-557. doi: 10.1038/s41581-018-0044-0. PMID: 30072710.
* Satoskar AA, Parikh SV, Nadasdy T. Epidemiology, pathogenesis, treatment and outcomes of infection-associated glomerulonephritis. Nat Rev Nephrol. 2020 Jan;16(1):32-50. doi: 10.1038/s41581-019-0178-8. Epub 2019 Aug 9. PMID: 31399725.
* Saadat-Gilani K, Zarbock A. Perioperative renal protection. Curr Opin Crit Care. 2021 Dec 1;27(6):676-685. doi: 10.1097/MCC.0000000000000881. PMID: 34534999.
* Baeza-Trinidad R. Rhabdomyolysis: A syndrome to be considered. Med Clin (Barc). 2022 Mar 25;158(6):277-283. doi: 10.1016/j.medcli.2021.09.025. Epub 2021 Dec 3. PMID: 34872769.
* Ross L. Acute Kidney Injury in Dogs and Cats. Vet Clin North Am Small Anim Pract. 2022 May;52(3):659-672. doi: 10.1016/j.cvsm.2022.01.005. Epub 2022 Apr 1. PMID: 35379499.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.